SAR443579 in AML, B-ALL, or MDS
Contact
Description
This study involves taking a study drug called SAR443579. The overall goal of this study is to find out if the study drug is safe and effective at treating adults and children with relapsed or refractory acute myeloid leukemia (R/R AML), high risk myelodysplastic syndrome (HR-MDS), or B-cell acute lymphoblastic leukemia (B-ALL). This is a first-in-human research study.
Eligibility and criteria
IRB Number:
23-021411
Eligible age range:
Clinical trial phase:
Phase I
Phase II
Official title:
What to expect
As a participant in the research, you will:
- Receive SAR443579 (study drug) infusions several times during each study cycle
- Complete frequent clinic visits at CHOP Philadelphia
- Stay in the hospital for 12 to 16 days after receiving the first dose of the study drug
- Have frequent blood and urine tests, including research tests to measure study drug levels
- Have a research electrocardiogram
- Submit leftover biopsy tissue and/or bone marrow aspirate to the study sponsor for research tests
- Complete questionnaires (adult participants only)
Related specialties
We need families like you
Your time and participation make a difference in supporting the work of the Research Institute and children in our community. Learn more about opportunities to participate in our research.